Literature DB >> 17240224

Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2alpha in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhea.

M Yusoff Dawood1, Firyal S Khan-Dawood.   

Abstract

OBJECTIVE: The purpose of this study was to compare acetaminophen with ibuprofen for pain relief and menstrual fluid prostaglandin F2alpha (PGF2alpha) suppression in primary dysmenorrhea. STUDY
DESIGN: Twelve subjects were randomized to placebo, acetaminophen (1000 mg orally, 4 x daily for 3 days) or ibuprofen (400 mg orally, 4 x daily for 3 days), once during each cycle in a prospective, double-blinded, crossover study. Using preweighed super absorbent tampons, menstrual fluid was collected, extracted, and PGF2alpha radioimmunoassayed.
RESULTS: Ten patients completed the study. Ibuprofen (P = .002) and acetaminophen (P = .022) were rated significantly better than placebo. Total menstrual fluid PGF2alpha with placebo was 36.2 + 6.1 microg but were 14.8 + 3.0 microg with ibuprofen (P = .001) and 21.4 + 3.4 microg with acetaminophen (P = .008). PGF2alpha concentrations with placebo were 0.34 + 0.054 microg/mL, with ibuprofen 0.16 + 0.026 microg/mL (P = .001), and with acetaminophen 0.23 + 0.029 microg/mL (P = .016).
CONCLUSION: Both ibuprofen and acetaminophen were superior to placebo for pain relief and menstrual fluid PGF2alpha suppression, with ibuprofen being more potent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17240224     DOI: 10.1016/j.ajog.2006.06.091

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  17 in total

1.  An overview of clinical pharmacology of Ibuprofen.

Authors:  Rabia Bushra; Nousheen Aslam
Journal:  Oman Med J       Date:  2010-07

2.  Comparative effect of cinnamon and Ibuprofen for treatment of primary dysmenorrhea: a randomized double-blind clinical trial.

Authors:  Molouk Jaafarpour; Masoud Hatefi; Ali Khani; Javaher Khajavikhan
Journal:  J Clin Diagn Res       Date:  2015-04-01

3.  PharmGKB summary: ibuprofen pathways.

Authors:  Liudmila L Mazaleuskaya; Katherine N Theken; Li Gong; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

Review 4.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

Review 5.  Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.

Authors:  Jane Marjoribanks; Reuben Olugbenga Ayeleke; Cindy Farquhar; Michelle Proctor
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30

6.  The effect of cinnamon on menstrual bleeding and systemic symptoms with primary dysmenorrhea.

Authors:  Molouk Jaafarpour; Masoud Hatefi; Fatemeh Najafi; Javaher Khajavikhan; Ali Khani
Journal:  Iran Red Crescent Med J       Date:  2015-04-22       Impact factor: 0.611

7.  Comparative evaluation of the efficacy of herbal drugs (fennelin and vitagnus) and mefenamic acid in the treatment of primary dysmenorrhea.

Authors:  Fatemeh Zeraati; Fatemeh Shobeiri; Mansour Nazari; Malihe Araghchian; Reza Bekhradi
Journal:  Iran J Nurs Midwifery Res       Date:  2014-11

8.  Flucrypyrim, a novel uterine relaxant, has antinociceptive and anti-inflammatory effects in vivo.

Authors:  Zhongtang Li; Limei Wang; Yue Cong; Lin Guo; Xiaohui Lin; Zuyin Yu; Xingan Wu; Junxing Dong; Rifang Yang; Yuwen Cong
Journal:  Sci Rep       Date:  2017-02-21       Impact factor: 4.379

9.  Moxibustion for pain relief in patients with primary dysmenorrhea: A randomized controlled trial.

Authors:  Mingxiao Yang; Xiangzhu Chen; Linna Bo; Lixing Lao; Jiao Chen; Siyi Yu; Zheng Yu; Hongzhi Tang; Ling Yi; Xi Wu; Jie Yang; Fanrong Liang
Journal:  PLoS One       Date:  2017-02-07       Impact factor: 3.240

10.  An in vivo mouse model of primary dysmenorrhea.

Authors:  Lu Yang; Zhengyu Cao; Boyang Yu; Chengzhi Chai
Journal:  Exp Anim       Date:  2015-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.